MedPath

Carbamazepine

CARBAMAZEPINE TABLETS USP, 200 mg / CARBAMAZEPINE TABLETS USP (CHEWABLE), 100 mg 0109   0778 Rx only

Approved
Approval ID

7f9ed987-5e34-4536-a22f-4898c9797e61

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 13, 2023

Manufacturers
FDA

NCS HealthCare of KY, LLC dba Vangard Labs

DUNS: 050052943

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Carbamazepine

PRODUCT DETAILS

NDC Product Code0615-3505
Application NumberANDA070541
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateSeptember 13, 2023
Generic NameCarbamazepine

INGREDIENTS (8)

CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
CARBAMAZEPINEActive
Quantity: 200 mg in 1 1
Code: 33CM23913M
Classification: ACTIB
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
ETHYLCELLULOSE (100 MPA.S)Inactive
Code: 47MLB0F1MV
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 9/13/2023

PACKAGE LABEL PRINCIPAL DISPLAY PANEL

Principal Display Panel-Carbamazepine 200mg Tab

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 9/13/2023

INDICATIONS AND USAGE

Epilepsy

Carbamazepine tablets USP and carbamazepine tablets USP (chewable) are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine tablets USP and carbamazepine tablets USP (chewable) as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:

1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types.

2. Generalized tonic-clonic seizures (grand mal).

3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine tablets USP and carbamazepine tablets USP (chewable) (seePRECAUTIONS,General).

Trigeminal Neuralgia

Carbamazepine tablets USP and carbamazepine tablets USP (chewable) are indicated in the treatment of the pain associated with true trigeminal neuralgia.

Beneficial results have also been reported in glossopharyngeal neuralgia.

This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

DESCRIPTION SECTION

LOINC: 34089-3Updated: 9/13/2023

DESCRIPTION

Carbamazepine, USP is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as chewable tablets of 100 mg and tablets of 200 mg. Its chemical name is 5H-dibenz[b,f]azepine-5-carboxamide, and its structural formula is:

Structural Formula: Carbamazapine Tablets

C15H12N2O M.W. 236.27

Carbamazepine, USP is a white to off-white powder, practically insoluble in water and soluble in alcohol and in acetone.

Carbamazepine tablets USP, 200 mg contain the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, ethylcellulose, glycerin, lactose monohydrate, magnesium stearate, and sodium starch glycolate.

Carbamazepine tablets USP (chewable), 100 mg contain the inactive ingredients acacia, colloidal silicon dioxide, croscarmellose sodium, ethylcellulose, FD&C Red #40 aluminum lake, flavoring, glycerin, lactose monohydrate, magnesium stearate, pregelatinized corn starch, and sucrose.

Carbamazepine tablets USP, 200 mg meet USP Dissolution Test 3.

Carbamazepine tablets USP (chewable), 100 mg meet USP Dissolution Test 1.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.